By Adriano Marchese
LifeMD on Thursday said it will integrate with Eli Lilly's online pharmacy and healthcare platform to offer access to Lilly's prescription obesity treatment Zepbound in single-dose vials.
LifeMD, a virtual primary care services provider, said it is integrating with Gifthealth which will make Lilly's single-dose vials of Zepbound accessible to the company's eligible patients.
Zepbound is available for on-label self-pay patients in vials with dosages between 2.5 milligrams and 10 milligrams through LillyDirect's self-pay pharmacy channel.
Recently, Lilly reduced the price of some offerings of its 2.5 and 5 milligram vials.
"This new integration complements our insurance-sponsored pharmacy programs, where we continue to see rising approval rates for branded GLP-1 therapies like Zepbound," LifeMD Chairman and Chief Executive Justin Schreiber said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
March 06, 2025 08:51 ET (13:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.